Search | Clinical Trials Finder

Conditions: Hypercholesterolemia
Interventions: LGT209, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Miami Gardens, Florida • Fargo, North Dakota

Conditions: Hyperphosphatemia
Interventions: DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more

Conditions: Endometrial Neoplasms
Interventions: olaparib, durvalumab, durvalumab placebo, olaparib placebo, Carboplatin, Paclitaxel; Drug · Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years · Female only
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 50
States / cities: Tucson, Arizona • Concord, California • La Jolla, California + 45 more

Conditions: Mild Traumatic Brain Injury, Suicidal Ideation, Impulsivity
Interventions: intermittent theta burst stimulation, placebo intermittent theta burst stimulation; Device
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 22 Years to 65 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Hines, Illinois

Conditions: Atopic Dermatitis
Interventions: GHZ339, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 24
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 20 more

Conditions: Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
Interventions: Ascorbic Acid, Carboplatin, Cisplatin, Cytarabine, Dexamethasone, Etoposide, Gemcitabine Hydrochloride, Ifosfamide, Laboratory Biomarker Analysis, Oxaliplatin, Placebo Administration, Questionnaire Administration, Rituximab, Decitabine, Biospecimen Collection, Core Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Echocardiography, Positron Emission Tomography, Magnetic Resonance Imaging, Central Venous Cannula Insertion, Portacath Placement, Computed Tomography, Decitabine and Cedazuridine; Dietary Supplement · Drug · Other + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 4
States / cities: Mankato, Minnesota • Rochester, Minnesota • Eau Claire, Wisconsin + 1 more

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Quizartinib, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 342
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 262 more

Conditions: Major Depressive Disorder
Interventions: Brexpiprazole, Antidepressant therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non Squamous, Non-small-cell Lung Cancer
Interventions: Tivantinib, Placebo, Erlotinib; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,048 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 111
States / cities: Tucson, Arizona • Los Angeles, California • Oxnard, California + 85 more

Conditions: Peanut Allergy
Interventions: Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg; Drug
Lead sponsor: Stanford University; Other
Eligibility: 7 Years to 55 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Mountain View, California

Conditions: Alzheimer's Disease
Interventions: Vitamin E, Vitamin C, and Alpha-lipoic Acid, Coenzyme Q, Placebo capsules, Placebo wafers; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 60 Years to 85 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 13
States / cities: Tucson, Arizona • Irvine, California • La Jolla, California + 10 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antioxidant supplement, Diabetes treatment, Regular Insulin; Dietary Supplement · Other · Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 12 Years to 21 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Hypercholesterolaemia
Interventions: Laroprovstat, Rosuvastatin 1, Rosuvastatin 2, Laroprovstat/Rosuvastatin 1, Placebo to match rosuvastatin, Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1, Laroprovstat/Rosuvastatin 2, Placebo to match Laroprovstat/Rosuvastatin 2; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 77
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more

Conditions: Acquired Immunodeficiency Syndrome, HIV Infections
Interventions: E/C/F/TDF, ATV, RTV, FTC/TDF, E/C/F/TDF Placebo, ATV Placebo, RTV Placebo, FTC/TDF Placebo, E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 583 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 41
States / cities: Los Angeles, California • Sacramento, California • Washington D.C., District of Columbia + 31 more

Conditions: Anxiety Disorders, Alcohol Use Disorder, Stress, Psychological
Interventions: active heat, Active c tactile fiber stimulation, sham heat, Sham c tactile fiber stimulation; Device · Drug
Lead sponsor: Soovu Labs Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Acromegaly
Interventions: Debio 4126, Placebo; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 7 more

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe; Biological · Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 615 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 47
States / cities: Birmingham, Alabama • Chandler, Arizona • Little Rock, Arkansas + 40 more

Conditions: Healthy Subjects
Interventions: Placebo, E2609, Moxifloxacin; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Covid19
Interventions: Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 473 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 40
States / cities: Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more

Conditions: Bladder Cancer
Interventions: Apaziquone, Placebo; Drug · Other
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Epilepsy
Interventions: BIA 2-093, Moxifloxacin, Placebo; Drug
Lead sponsor: Bial - Portela C S.A.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Uncontrolled Postoperative Pain
Interventions: 0.375% ROPIVACAINE, placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 40 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Edematous, Synovitis, Foreign Body Reaction, Osteolysis
Interventions: Placebo, Apatone®B; Drug
Lead sponsor: IC-MedTech Corporation; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Akron, Ohio

Search by objective public record fields.

Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

Frontal iTBS for Impulsivity and Suicidal Ideation in Veterans With Mild Traumatic Brain Injury

Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

Anti-Oxidant Treatment of Alzheimer's Disease

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Treating Stress and Anxiety in Individuals With Alcohol Use Disorder (AUD)

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2

A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

Double-Blinded Clinical Trial Using Apatone®B for Symptomatic Postoperative Total Joint Replacements